- Home
- MOLN vs DMAC Comparison
MOLN vs DMAC Comparison
Compare MOLN & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- DMAC
- Stock Information
- Founded
- MOLN 2004
- DMAC 2000
- Country
- MOLN Switzerland
- DMAC United States
- Employees
- MOLN N/A
- DMAC N/A
- Industry
- MOLN
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- DMAC Health Care
- Exchange
- MOLN Nasdaq
- DMAC Nasdaq
- Market Cap
- MOLN 195.4M
- DMAC 224.6M
- IPO Year
- MOLN 2021
- DMAC N/A
- Fundamental
- Price
- MOLN $5.56
- DMAC $5.71
- Analyst Decision
- MOLN
- DMAC Strong Buy
- Analyst Count
- MOLN 0
- DMAC 3
- Target Price
- MOLN N/A
- DMAC $7.00
- AVG Volume (30 Days)
- MOLN 7.1K
- DMAC 100.7K
- Earning Date
- MOLN 03-13-2025
- DMAC 11-13-2024
- Dividend Yield
- MOLN N/A
- DMAC N/A
- EPS Growth
- MOLN N/A
- DMAC N/A
- EPS
- MOLN N/A
- DMAC N/A
- Revenue
- MOLN $7,105,397.00
- DMAC N/A
- Revenue This Year
- MOLN N/A
- DMAC N/A
- Revenue Next Year
- MOLN $29.41
- DMAC N/A
- P/E Ratio
- MOLN N/A
- DMAC N/A
- Revenue Growth
- MOLN N/A
- DMAC N/A
- 52 Week Low
- MOLN $3.32
- DMAC $2.14
- 52 Week High
- MOLN $12.70
- DMAC $6.41
- Technical
- Relative Strength Index (RSI)
- MOLN 53.39
- DMAC 56.89
- Support Level
- MOLN $4.98
- DMAC $4.88
- Resistance Level
- MOLN $5.91
- DMAC $5.85
- Average True Range (ATR)
- MOLN 0.27
- DMAC 0.39
- MACD
- MOLN 0.08
- DMAC -0.01
- Stochastic Oscillator
- MOLN 69.45
- DMAC 77.57
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.